Business news, market intelligence, and global industry analysis.
The Latest

Zydus Lifesciences gets FDA final approval for Ofirmev generic

byPallavi Madhiraju
October 30, 2022
Zydus Lifesciences gets FDA final approval for Ofirmev generic — Acetaminophen Injection
Zydus Lifesciences gets FDA final approval for Ofirmev generic — Acetaminophen Injection. Photo courtesy of Zydus Cadila.
Total
0
Shares
0
0
0

Zydus Lifesciences Limited (formerly Cadila Healthcare) said that it has secured final approval from the US Food and Drug Administration (FDA) for Acetaminophen Injection, 1,000 mg/100 mL (10 mg/mL) single-dose vials.

The product is the generic of Ofirmev. It is approved for easing mild to moderate pain and bringing down fever. Ofirmev also has the approval to be used in combination with opioid (narcotic) drugs for relieving pain that is at moderate to severe levels.

Zydus Lifesciences will manufacture Acetaminophen Injection at its injectable manufacturing plant in Jarod, near Vadodara.

Zydus Lifesciences gets FDA final approval for Ofirmev generic — Acetaminophen Injection
Zydus Lifesciences gets FDA final approval for Ofirmev generic — Acetaminophen Injection. Photo courtesy of Zydus Cadila.

According to IQVIA MAT Aug 2022, Acetaminophen injection had sales of $72 million in the US.

Zydus Lifesciences said that it currently has 330 approvals and to date filed more than 428 abbreviated new drug applications (ANDAs) since the start of the filing process in FY 2003-04.

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

See also  Astellas, Pfizer bag Xtandi FDA approval for non-metastatic CRPC
Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Mallinckrodt to sell Canadian CDMO BioVectra to H.I.G. Capital for $250m

Mallinckrodt sale of BioVectra to H.I.G. Capital : Irish biopharma company Mallinckrodt has agreed to divest its wholly-owned subsidiary BioVectra, a Canadian CDMO (contract development and manufacturing organization) to an affiliate of H.I.G. Capital for nearly US$250 million, as per the latest pharma acquisition news. The transaction amount to be paid by H.I.G. Capital, which is […]

The post Mallinckrodt to sell Canadian CDMO BioVectra to H.I.G. Capital for $250m appeared first on PharmaNewsDaily.com.

bySrinath